期刊
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
卷 38, 期 11-12, 页码 1365-1372出版社
WILEY
DOI: 10.1111/apt.12523
关键词
-
资金
- Roche Diagnostics
- Roche Pharma
- Merck/MSD
- Abbott Molecular
- Roche
- Janssen-Cilaq
- BMS
- Gilead
- Boehringer Ingelheim
- Novartis
- Tibotec
- Vertex
- GSK
- Merck
- Transgene
- Abbott
- Falk
- ITF
- German Federal Ministry of Education and Research (Bundesministerium fur Bildung und Forschung
- BMBF) [37]
BackgroundDrug-drug interactions (DDIs) in the treatment of chronic hepatitis C infection became a potential challenge with the introduction of direct-acting anti-virals (DAAs). Both currently approved DAAs, the protease inhibitors (PIs) telaprevir (TVR) and boceprevir (BOC), are substrates and inhibitors of P-glycoprotein and the cytochrome P450 3A4, which are regularly involved in DDIs. AimTo analyse the risk for DDIs in patients with chronic HCV genotype 1 infection considered for PI treatment at a tertiary referral centre. MethodsThe first 115 consecutive patients selected for a PI therapy at Hannover Medical School were included. All changes to co-medication before and during PI treatment were documented. Drugs were checked for DDIs with TVR and BOC using DDI websites and the respective prescribing information. ResultsOut-patient medication contained 116 different drugs. Median number of drugs/patient was 2 (range 0-11). The risk for DDIs was substantial for 38% of the drugs affecting 49% of patients. Only 4% of the drugs were strictly contraindicated. DDIs between a PI and drugs newly prescribed during anti-viral therapy were considerable in 42% of the patients. Suspected DDIs were managed by dose adjustments and discontinuation of co-medication in 7% and 21% of the patients respectively. ConclusionsMany patients with chronic HCV genotype 1 infection are affected by potential DDIs if treated with a protease inhibitor, but only in a minority of cases co-medication is strictly incompatible. Overall, the challenge of DDIs is time-consuming, but well manageable by a careful review of the patient's drug chart and monitoring during treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据